Notice2022-04970
Grant of Interim Extension of the Term of U.S. Patent No. 6,953,476; Reducer®
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
March 9, 2022
Issuing agencies
Commerce DepartmentPatent and Trademark Office
Abstract
The United States Patent and Trademark Office has issued an order granting a one-year interim extension of the term of U.S. Patent No. 6,953,476.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 46 (Wednesday, March 9, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 46 (Wednesday, March 9, 2022)]
[Notices]
[Page 13278]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-04970]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No.: PTO-P-2022-0003]
Grant of Interim Extension of the Term of U.S. Patent No.
6,953,476; Reducer[supreg]
AGENCY: United States Patent and Trademark Office, Department of
Commerce.
ACTION: Notice of interim patent term extension.
-----------------------------------------------------------------------
SUMMARY: The United States Patent and Trademark Office has issued an
order granting a one-year interim extension of the term of U.S. Patent
No. 6,953,476.
FOR FURTHER INFORMATION CONTACT: Ali Salimi, Senior Legal Advisor,
Office of Patent Legal Administration, by telephone at 571-272-0909 or
by email to <a href="/cdn-cgi/l/email-protection#e1808d88cf92808d888c88a1949291958ecf868e97"><span class="__cf_email__" data-cfemail="08696461267b6964616561487d7b787c67266f677e">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code,
generally provides that the term of a patent may be extended for a
period of up to five years if the patent claims a product, or a method
of making or using a product, that has been subject to certain defined
regulatory review, and that the patent may be extended for interim
periods of up to one year if the regulatory review is anticipated to
extend beyond the expiration date of the patent.
On February 22, 2022, Neovasc Medical Ltd., the patent owner of
record, timely filed an application under 35 U.S.C. 156(d)(5) for a
third interim extension of the term of U.S. Patent No. 6,953,476. The
patent claims a catheter delivered implantable device, Reducer[supreg].
The application for patent term extension indicates that a Premarket
Approval Application (PMA) P190035 was submitted to the Food and Drug
Administration (FDA) on December 31, 2019. Review of the patent term
extension application indicates that, except for permission to market
or use the product commercially, the subject patent would be eligible
for an extension of the patent term under 35 U.S.C. 156, and that the
patent should be extended for one year as required by 35 U.S.C.
156(d)(5)(B). Because the regulatory review period will continue beyond
the extended expiration date of the patent, March 27, 2022, interim
extension of the patent term under 35 U.S.C. 156(d)(5) is appropriate.
An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S.
Patent No. 6,953,476 is granted for a period of one year from the
extended expiration date of the '476 patent.
Robert Bahr,
Deputy Commissioner for Patents, United States Patent and Trademark
Office.
[FR Doc. 2022-04970 Filed 3-8-22; 8:45 am]
BILLING CODE 3510-16-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on March 9, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.